

Cuba and France Sign Joint Accord in Pharmaceutical Sector



Havana, February 12 (RHC)-- France's Abivax company and Cuba's Genetic Engineering and Biotechnology Center have announced a bilateral association accord to develop and market medications, including the Cuban Hepatitis B vaccine.

The Havana-based scientific center has developed some 50 different projects, while Abivax, based in Paris, was created by the merger of the Wittycell, Splicos and Zophis companies with the objective of fighting both cancer and infectious diseases.

The head of the marketing department at Cuba's Biocubafarma company, Norkis Arteaga, announced the bilateral accord between the French and the Cuban entities to market the Hepatitis B vaccine, which has had encouraging results both on the island and abroad.

Arteaga added that the accord stipulates that Cuba will contribute data on the vaccine and its potential capacity, while the French company will allocate financial resources to complete other research studies in Europe and Asia and share its experience of registering the vaccine in those markets and its further promotion.

<https://www.radiohc.cu/index.php/en/noticias/nacionales/14293-cuba-and-france-sign-joint-accord-in-pharmaceutical-sector>



Radio Habana Cuba